James R. Porter, Ph.D., is the President and Chief Executive Officer at Nuvation Bio Inc., a biopharmaceutical company focused on developing novel therapies for cancer. Dr. Porter has been instrumental in guiding Nuvation Bio's strategic direction and growth since its inception. Prior to joining Nuvation Bio, he held several key leadership positions in the biopharmaceutical industry, including roles at Novartis AG and Agios Pharmaceuticals, where he honed his skills in drug development and corporate strategy. Dr. Porter's academic background is equally impressive, having earned his Ph.D. in Biochemistry from the University of California, San Francisco. His research focused on understanding the molecular mechanisms of cancer, laying the groundwork for his future career in oncology drug development. Throughout his career, Dr. Porter has been recognized for his contributions to the field, receiving numerous awards and accolades for his leadership and scientific achievements. As President and CEO of Nuvation Bio, Dr. Porter oversees all aspects of the company's operations, from research and development to clinical trials and commercialization efforts. Under his leadership, Nuvation Bio has made significant progress in advancing its pipeline of innovative cancer therapies, with several promising drug candidates currently in clinical development. Dr. Porter's vision and expertise continue to drive Nuvation Bio's mission to transform the treatment landscape for cancer patients worldwide.